The US FDA has cleared V.A.C.®Via™ Negative Pressure Wound Therapy System from Kinetic Concepts, Inc.(KCI), featuring a diaphragm pump for faster draw down, longer battery life and higher leak rate threshold than its forebear.
Operating on a global scale, KCI has recently acquired Systagenix and Lifecell Corporation and is combining its resources to form one globally diversified wound care, biologics and regenerative medicine company, committed to advancing the science of medicine to reduce complications, speed healing and improve patient lives.
V.A.C® refers to vacuum assisted closure, which is KCI’s interpretation of negative pressure wound therapy. The company’s V.A.C.Via™ Therapy System is a single patient use, ultra-portable V.A.C. Therapy System that provides simplified wound care for patients with moderate- to low-exudating wounds.
KCI says the newly cleared system enhancements make the system both effective and convenient for patients. For a start it offers a discreet, portable device which is better for patients and clinicians who can benefit from the convenience of having easy access to an off-the-shelf, single-patient-use device. KCI says hospitals will appreciate the potential cost savings of reduced length of stay. The V.A.C.Via™ Therapy System can be used in the acute setting for patients transitioning home and who are in need of continued V.A.C.® Therapy. The product will be available in the US in early December.
“We’ve listened to the feedback from our customers and patients and have taken our original system and enhanced it to better meet their needs,” said Jim Cunniff, senior vice president, Americas, KCI. “The V.A.C.Via™ Therapy Unit is designed to help patients return to their normal lifestyle, while receiving up to seven days of negative pressure wound therapy in a compact, portable unit.”
Source: Kinetic Concepts, Inc.